Exploring Forensic Data with Self-Organizing Maps

Bennie Fei,J. Eloff,H. Venter,M. Olivier

DOI: https://doi.org/10.1007/0-387-31163-7_10

2005-02-13

Abstract:

What problem does this paper attempt to address?

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses

Oliver FitzGerald,Dafna D. Gladman,Philip J. Mease,Christopher Ritchlin,Josef S. Smolen,Lu Gao,Yanhua Hu,Miroslawa Nowak,Subhashis Banerjee,Ian Catlett

DOI: https://doi.org/10.1002/art.42921

2024-05-22

Arthritis & Rheumatology

Abstract:Objective To evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and relationship between biomarkers and clinical responses to deucravacitinib. Methods The phase 2 trial (NCT03881059) randomized 203 patients with PsA 1:1:1 to placebo, deucravacitinib 6 mg once daily (QD), or deucravacitinib 12 mg QD. Serum biomarkers associated with the IL‐23 pathway (IL‐17A, BD‐2, and IL‐19), Type I interferon pathway, inflammation, and collagen matrix turnover were measured by immunoassay. Clinical responses (≥75% improvement from baseline in Psoriasis Area and Severity Index [PASI 75] and ≥20% improvement from baseline in American College of Rheumatology [ACR 20] criteria responses) were measured at week 16. Hematologic variables were also assessed. Results IL‐17A, BD‐2, and IL‐19 had a modest association with PASI scores (r=0.4, r=0.56, and r=0.5, respectively) at baseline. In deucravacitinib groups, IL‐17A, BD‐2, IL‐19, CXCL‐9, CXCL‐10, CRP, MMP3, and C4M levels were significantly reduced at week 16 versus baseline (P<0.01); higher levels of IL‐23 pathway‐associated biomarkers predicted higher PASI 75 and ACR 20 response rates in deucravacitinib‐treated patients. Significantly higher PASI 75 response rates were seen in patients with high baseline IL‐17A (OR: 15.76) and BD‐2 (OR: 15.41) versus low. Changes in hematologic variables that are characteristic of JAK inhibition were not observed with deucravacitinib. Conclusion Deucravacitinib significantly impacted biomarkers associated with TYK2 signaling pathways of key inflammatory cytokines, including IL‐23 and Type I IFN, and those related to collagen matrix turnover. These biomarkers may predict treatment responses to deucravacitinib.

rheumatology
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis

Marco Galluzzo,Laura Vellucci,Lorenzo Marcelli,Claudia Paganini,Luca Bianchi,Marina Talamonti

DOI: https://doi.org/10.1080/14656566.2023.2211764

Abstract:Introduction: Protein kinases play a crucial role in intracellular signaling pathways that lead to inflammation and cell proliferation. New understandings of the involvement of these metabolic pathways in the pathogenesis of psoriasis allowed the development of a new class of drugs. Unlike biologics, these compounds work by blocking intracellular targets involved in the immune response. Areas covered: Deucravacitinib is an oral small-molecule inhibitor of TYK2 that binds the pseudokinase domain and locks the kinase in an inactive state by an allosteric mechanism, arresting TYK2-mediated signaling cascades and disabling the upregulation of proinflammatory genes implicated in psoriasis. The authors present the results of phase I-III clinical trials of deucravacitinib for the treatment of psoriasis. Expert opinion: At week 16 about 56% of the patients treated with deucravacitinib achieved PASI75. No serious infections were reported, nor were thromboembolic events or laboratory abnormalities. Efficacy was reported to be persistent and safety profiles were shown to be consistent for up to 2 years. Deucravacitinib can potentially become a safe, effective, well-tolerated treatment for patients suffering from moderate-to-severe disease. Future studies and real-life experiences will be important to determine the exact role of this drug in the treatment of psoriasis.
Deucravacitinib for the Treatment of Psoriatic Disease

Ana Maria Lé,Luis Puig,Tiago Torres

DOI: https://doi.org/10.1007/s40257-022-00720-0

Abstract:Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for mediating immune signalling of IL-12, IL-23 and type I interferons, without interfering with other critical systemic functions as other JAK proteins do. This article aims to review the current knowledge on deucravacitinib, a new oral drug that selectively inhibits TYK2, granting it a low risk of off-target effects. After good efficacy and safety results in a phase II, placebo-controlled trial, two phase III, 52-week trials evaluated deucravacitinib 6 mg against placebo and apremilast-an active comparator. POETYK PSO-1 and PSO-2 involved 1688 patients with moderate-to-severe psoriasis. After 16 weeks, in both studies, over 50% of patients treated with deucravacitinib reached PASI75, which was significantly superior to placebo and apremilast. In POETYK PSO-1, these results improved until week 24 and were maintained through week 52, with over 65% of patients achieving PASI75 at this point. A reduction in signs and symptoms was also reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromboembolic events, or laboratory abnormalities, which are a concern among other JAK inhibitors. Persistent efficacy and consistent safety profiles were reported for up to 2 years. Despite advances in the treatment of psoriasis, namely among biologic agents, an oral, effective and safe new drug can bring several advantages to prescribers and patients. Further investigation is required to understand where to place deucravacitinib among current psoriasis treatment options.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Bruce Strober,Diamant Thaçi,Howard Sofen,Leon Kircik,Kenneth B Gordon,Peter Foley,Phoebe Rich,Carle Paul,Jerry Bagel,Elizabeth Colston,John Throup,Sudeep Kundu,Chitra Sekaran,Misti Linaberry,Subhashis Banerjee,Kim A Papp

DOI: https://doi.org/10.1016/j.jaad.2022.08.061

Abstract:Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits cytokine signaling in psoriasis pathogenesis. Objective: The objective of this study was to demonstrate deucravacitinib superiority versus placebo and apremilast in moderate to severe plaque psoriasis based on ≥75% reduction from baseline in Psoriasis Area and Severity Index and a static Physician's Global Assessment score of 0 (clear) or 1 (almost clear) with a ≥2-point improvement from baseline at week 16. Methods: POETYK psoriasis second trial (NCT03611751), a 52-week, double-blinded, phase 3 trial, randomized patients 2:1:1 to deucravacitinib 6 mg every day (n = 511), placebo (n = 255), or apremilast 30 mg twice a day (n = 254). Results: At week 16, significantly more deucravacitinib-treated patients versus placebo and apremilast patients achieved ≥75% reduction from baseline in Psoriasis Area and Severity Index (53.0% vs 9.4% and 39.8%; P < .0001 vs placebo; P = .0004 vs apremilast) and static Physician's Global Assessment score of 0 or 1 (49.5% vs 8.6% and 33.9%; P < .0001 for both). Efficacy was maintained until week 52 with continuous deucravacitinib. The most frequent adverse event with deucravacitinib was nasopharyngitis. Serious adverse events and discontinuations due to adverse events were infrequent. No clinically meaningful changes were observed in laboratory parameters. Limitations: The study duration was 1 year. Conclusion: Deucravacitinib demonstrated superiority versus placebo and apremilast and was well tolerated in adults with moderate to severe plaque psoriasis.
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

April W Armstrong,Matthias Augustin,Jennifer L Beaumont,Tan P Pham,Stacie Hudgens,Kenneth B Gordon,Joe Zhuo,Brandon Becker,Yichen Zhong,Renata M Kisa,Subhashis Banerjee,Kim A Papp

DOI: https://doi.org/10.1007/s13555-024-01224-x

Abstract:Introduction: Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib treatment versus placebo and apremilast in these studies. Methods: Two multicenter, global, double-blind, placebo- and active comparator-controlled studies randomized patients with moderate-to-severe plaque psoriasis 1:2:1 to placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. Score changes from baseline and meaningful within-patient change responses for Psoriasis Symptoms and Signs Diary (PSSD) and Dermatology Life Quality Index (DLQI) were assessed. Results: In POETYK PSO-1 (n = 666) and PSO-2 (n = 1020), respectively, improvement from baseline in PSSD total score was greater with deucravacitinib (- 27.8 and - 30.1) versus placebo (- 4.4 and - 5.9) and apremilast (- 18.9 and - 22.5) at Week 16 and versus apremilast at Week 24 (deucravacitinib: - 32.8 and - 30.7; apremilast: - 21.6 and - 22.8) (nominal p < 0.0001). Improvement from baseline in DLQI score was also greater with deucravacitinib (- 8.5 and - 7.6) versus placebo (- 3.3 and - 3.0) and apremilast (- 5.9 and - 5.8) at Week 16 and versus apremilast at Week 24 (deucravacitinib: - 8.6 and - 7.5; apremilast: - 5.6 and - 5.5) (nominal p < 0.0001). Achievement of meaningful within-patient change in PSSD total score and in DLQI score occurred more frequently with deucravacitinib than placebo and apremilast at Week 16 and versus apremilast at Week 24. Conclusions: Deucravacitinib demonstrated meaningful improvements in patient-reported outcomes in patients with moderate-to-severe plaque psoriasis compared with apremilast and placebo. Clinical trial registration: NCT03624127, NCT03611751.
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis

Paige Kingston,Andrew Blauvelt,Bruce Strober,April W. Armstrong

DOI: https://doi.org/10.1177/24755303231201336

2023-09-05

Journal of Psoriasis and Psoriatic Arthritis

Abstract:Background Deucravacitinib is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of adults with moderate-to-severe plaque psoriasis. Objective To discuss the mechanism of action, efficacy, safety, and real-world applications of deucravacitinib for the treatment of psoriasis. Methods Literature on the mechanism of action of deucravacitinib is reviewed. The pivotal clinical studies and long-term extension studies for deucravacitinib are also examined. Results Deucravacitinib is a novel oral TYK2 inhibitor that binds to the regulatory domain of TYK2, a Janus kinase. By inhibiting TYK2, deucravacitinib interferes with signaling of IL-23, IL-12, and type I interferons, cytokines believed to play important roles in psoriasis pathogenesis. Nearly 60% of patients achieve PASI 75 at 16 weeks of treatment; efficacy improves over 24 weeks and is maintained through 2 years of continuous treatment. In a head-to-head comparison, deucravacitinib efficacy was superior to apremilast, an older yet commonly used oral PDE4 inhibitor approved for the treatment of psoriasis. Of note, patients with moderate-to-severe plaque psoriasis with concomitant involvement of the scalp, nails, and/or palms/soles demonstrated good improvement in these high impact areas. Deucravacitinib has an acceptable safety profile and is generally well-tolerated. Small increases in reactivation of herpesvirus infections, including herpes simplex outbreaks, have been reported. Tuberculosis evaluation, but no other blood tests, is recommended prior to initiation of deucravacitinib. Monitoring of triglyceride levels should be conducted for high-risk patients according to local guidelines. Conclusion Deucravacitinib is an effective, safe, and well-tolerated novel oral medication for adults with moderate-to-severe plaque psoriasis.
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients from China Mainland, Taiwan, and South Korea with Moderate to Severe Plaque Psoriasis: a Phase 3 Randomized Clinical Trial

Jianzhong Zhang,Yangfeng Ding,Ping Wang,Linfeng Li,Weili Pan,Yan Lu,Hao Cheng,Xian Jiang,Ji-Chen Ho,Shuping Guo,Leona Liu,Arkendu Chatterjee,Renata M Kisa,Subhashis Banerjee

DOI: https://doi.org/10.1093/bjd/ljae406

2024-01-01

Abstract:BACKGROUND:Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the United States, European Union, Japan, South Korea, China, and other countries for treatment of moderate-to-severe plaque psoriasis. OBJECTIVE:To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate to severe plaque psoriasis. METHODS:In the 52-week, blinded, phase 3 POETYK PSO-3 trial (NCT04167462), patients were randomized 1 : 2 to placebo (n = 74) or deucravacitinib 6 mg once daily (n = 146) for 16 weeks followed by deucravacitinib alone. Coprimary endpoints were achievement of ≥ 75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear) (sPGA 0/1) at Week 16. Efficacy and safety were evaluated throughout. RESULTS:At Week 16, significantly higher proportions of patients receiving deucravacitinib versus placebo achieved PASI 75 (68.8% vs. 8.1%; P < 0.0001) and sPGA 0/1 (55.6% vs. 6.8%; P < 0.0001). Response rates with deucravacitinib were maintained through Week 52. Common adverse events included upper respiratory tract infection and nasopharyngitis. Serious adverse event and discontinuation rates were low. CONCLUSIONS:Deucravacitinib was efficacious and well tolerated in Asian patients with moderate to severe plaque psoriasis.
Deucravacitinib in the treatment of psoriasis

Tomás Estevinho,Ana Maria Lé,Tiago Torres

DOI: https://doi.org/10.1080/09546634.2022.2154122

2022-12-14

Journal of Dermatological Treatment

Abstract:Psoriasis is a chronic, immune-mediated, skin disease with a significantly negative impact on patients' quality of life. Moderate-to-severe disease often requires systemic therapies and currently available ones still have numerous disadvantages or limitations. Tyrosine kinase 2 (TYK2) mediates immune signaling of IL-12, IL-23, and type I interferons, without interfering with other critical systemic functions. This article aims to review the current knowledge on deucravacitinib, a new oral drug which selectively inhibits TYK2, granting it a low risk of off-target effects. A review of the published literature was conducted using the PubMed database, published abstracts and virtual presentations from scientific meetings, data from industry press releases, and results published on ClinicalTrials.gov regarding the deucravacitinib for the treatment of psoriasis. Manuscripts with trial results, case series, clinical trial data from ClinicalTrials.gov, and articles highlighting expert perspectives on the topic of the article were selected. Two phase 3, 52-week trials evaluated deucravacitinib 6 mg against placebo and apremilast – POETYK PSO-1 and PSO-2, enrolling 1688 patients with moderate-to-severe psoriasis. At week 16, over 50% of patients treated with deucravacitinib reached PASI75, significantly superior to placebo and apremilast. Symptomatic improvement was also reported, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromboembolic events, or laboratory abnormalities. Persistent efficacy and consistent safety profiles were reported for up to 2 years. Deucravacitinib has the potential to become a safe, effective, and well-tolerated treatment for patients with moderate-to-severe disease. Future studies will be important to determine the exact role of this drug in the treatment of psoriasis.

dermatology
Confronting competing demands to improve quality: a five-country hospital survey.

R. Blendon,C. Schoen,C. DesRoches,R. Osborn,K. Zapert,E. Raleigh

DOI: https://doi.org/10.1377/HLTHAFF.23.3.119

2004-05-01

Health Affairs

Abstract:This paper reports on a 2003 comparative survey of hospital executives in Australia, Canada, New Zealand, the United Kingdom, and the United States. Reflecting higher spending levels, U.S. hospitals as a group stand out for generally more positive ratings of facilities and finances and short or no waiting times. Yet U.S. hospital executives are also the most negative about their country's health care system. Hospital executives in all five countries expressed concerns about staffing shortages and emergency department waiting times and quality. Asked about future strategies to improve quality, executives in all five countries expressed support for making information technology an investment priority.
Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Melinda J Gooderham,H Chih-Ho Hong,Ivan V Litvinov

Abstract:Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need. Oral deucravacitinib is a first-inclass selective TYK2 inhibitor, which has shown efficacy in moderate to severe chronic plaque psoriasis from two phase III pivotal trials (POETYK PSO-1 and PSO-2), whereby response rates were significantly higher with deucravacitinib vs. placebo or apremilast for Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1. Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast. Although deucravacitinib is a type of Janus kinase (JAK) inhibitor, it only blocks specific cytokine-driven responses, potentially reducing off-target effects more commonly associated with other JAK inhibitors on the market. Incidence rates of serious adverse events, such as serious infections, malignancies, thrombosis, cardiovascular events, creatinine kinase elevation, hematologic changes, and lipid profile abnormalities were absent or low.
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Bruce Strober,Andrew Blauvelt,Richard B. Warren,Kim A. Papp,April W. Armstrong,Kenneth B. Gordon,Akimichi Morita,Andrew F. Alexis,Mark Lebwohl,Peter Foley,Renata M. Kisa,Elizabeth Colston,Tao Wang,Subhashis Banerjee,Diamant Thaçi

DOI: https://doi.org/10.1111/jdv.19925

2024-03-09

Journal of the European Academy of Dermatology and Venereology

Abstract:Background Two phase 3 trials, POETYK PSO‐1 and PSO‐2, previously established the efficacy and overall safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in plaque psoriasis. Objectives To further assess the safety of deucravacitinib over 52 weeks in the pooled population from these two trials. Methods Pooled safety data were evaluated from PSO‐1 and PSO‐2 in which patients with moderate‐to‐severe plaque psoriasis were randomized 1:2:1 to receive oral placebo, deucravacitinib or apremilast. Results A total of 1683 patients were included in the pooled analysis. Adverse event (AE) incidence rates were similar in each treatment group, serious AEs were low and balanced across groups, and discontinuation rates were lower with deucravacitinib versus placebo or apremilast. No new safety signals emerged with longer deucravacitinib treatment. Exposure‐adjusted incidence rates of AEs of interest with placebo, deucravacitinib and apremilast, respectively, were as follows: serious infections (0.8/100 person‐years [PY], 1.7/100 PY, and 1.8/100 PY), major adverse cardiovascular events (1.2/100 PY, 0.3/100 PY, and 0.9/100 PY), venous thromboembolic events (0, 0.2/100 PY, and 0), malignancies (0, 1.0/100 PY and 0.9/100 PY), herpes zoster (0.4/100 PY, 0.8/100 PY, and 0), acne (0.4/100 PY, 2.9/100 PY, and 0) and folliculitis (0, 2.8/100 PY, and 0.9/100 PY). No clinically meaningful changes from baseline in mean levels, or shifts from baseline to CTCAE grade ≥3 abnormalities, were reported in laboratory parameters with deucravacitinib. Conclusions Deucravacitinib was well‐tolerated with acceptable safety over 52 weeks in patients with psoriasis.

dermatology
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis

Andrew Blauvelt,Phoebe Rich,Howard Sofen,Bruce Strober,Joseph F Merola,Mark Lebwohl,Akimichi Morita,Jacek C Szepietowski,Jo Lambert,Lauren Hippeli,Elizabeth Colston,Eugene Balagula,Subhashis Banerjee,Diamant Thaçi

DOI: https://doi.org/10.1016/j.jaad.2023.11.060

Abstract:Background: Scalp involvement in plaque psoriasis is challenging to treat. Objective: To evaluate the efficacy and safety of deucravacitinib (DEUC) in scalp psoriasis. Methods: POETYK PSO-1 and PSO-2 were global phase 3, 52-week, double-blinded trials in adults with moderate to severe psoriasis. Patients were randomized 1:2:1 to oral placebo, DEUC 6 mg once daily, or apremilast 30 mg twice daily. This pooled secondary analysis evaluated scalp-specific Physician Global Assessment score of 0 or 1 (0/1), ≥90% improvement from baseline in Psoriasis Scalp Severity Index, and change from baseline in Psoriasis Scalp Severity Index. Adverse events were evaluated through week 16. Results: Overall, 1084 patients with moderate to severe scalp psoriasis at baseline were included. At week 16, response rates were greater with DEUC versus placebo or apremilast for scalp-specific Physician Global Assessment 0/1 (64.0% vs 17.3% vs 37.7%; P < .0001), ≥90% improvement from baseline in Psoriasis Scalp Severity Index (50.6% vs 10.5% vs 26.1%; P < .0001), and change from baseline in Psoriasis Scalp Severity Index. Responses were maintained through 52 weeks with continuous DEUC. Safety was consistent with the entire study population. Limitations: Lack of data in milder scalp psoriasis. Conclusion: DEUC was significantly more efficacious than placebo or apremilast in improving moderate to severe scalp psoriasis and was well tolerated.
Improvements in patient‐reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

Vibeke Strand,Laure Gossec,Laura C. Coates,Alexis Ogdie,Jiyoon Choi,Brandon Becker,Joe Zhuo,Thomas Lehman,Miroslawa Nowak,Ayanbola Elegbe,Philip J. Mease,Atul Deodhar

DOI: https://doi.org/10.1002/acr.25333

2024-03-28

Arthritis Care & Research

Abstract:Objective Deucravacitinib, a TYK‐2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient perspective. Methods This phase 2, double‐blind trial (NCT03881059) randomized patients with active PsA 1:1:1 to deucravacitinib 6 mg once daily (QD), 12 mg QD, or placebo, for 16 weeks. Key secondary endpoints were change from baseline (CFB) at Week 16 in Health Assessment Questionnaire Disability Index (HAQ‐DI) and 36‐item Short Form Health Survey (SF‐36) physical component summary (PCS) score. Additional patient‐reported outcomes (PROs) assessed disease impact, including fatigue, pain, and mental health. Mean CFB in PROs and percentages of patients reporting improvements with minimum clinically important differences (MCIDs) or scores of ≥ normative values were also assessed. Results This study comprised 203 patients (51.2% female; mean [SD] age, 49.8 [13.5] years). At Week 16, adjusted mean difference (95% CI) versus placebo in HAQ‐DI and SF‐36 PCS CFB was significant for each deucravacitinib group (HAQ‐DI 6 mg: −0.26 [−0.42, −0.10], P = 0.0020; HAQ‐DI 12 mg: −0.28 [−0.45, −0.12], P = 0.0008; SF‐36 PCS 6 mg: 3.3 [0.9, 5.7], P = 0.0062; SF‐36 PCS 12 mg: 3.5 [1.1, 5.9], P = 0.0042). MCID at Week 16 were reported for all PROs with either dose of deucravacitinib. Improvements of MCID or to normative values were reported by more patients receiving deucravacitinib than placebo. Conclusion Deucravacitinib demonstrated significant and clinically meaningful improvements in PROs versus placebo in patients with active PsA and warrants further study. This article is protected by copyright. All rights reserved.

rheumatology
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

April W Armstrong,Melinda Gooderham,Richard B Warren,Kim A Papp,Bruce Strober,Diamant Thaçi,Akimichi Morita,Jacek C Szepietowski,Shinichi Imafuku,Elizabeth Colston,John Throup,Sudeep Kundu,Steve Schoenfeld,Misti Linaberry,Subhashis Banerjee,Andrew Blauvelt

DOI: https://doi.org/10.1016/j.jaad.2022.07.002

Abstract:Background: Effective, well-tolerated oral psoriasis treatments are needed. Objective: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis. Methods: Participants were randomized 2:1:1 to deucravacitinib 6 mg every day (n = 332), placebo (n = 166), or apremilast 30 mg twice a day (n = 168) in the 52-week, double-blinded, phase 3 POETYK PSO-1 trial (NCT03624127). Coprimary end points included response rates for ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) with deucravacitinib versus placebo at week 16. Results: At week 16, response rates were significantly higher with deucravacitinib versus placebo or apremilast for PASI 75 (194 [58.4%] vs 21 [12.7%] vs 59 [35.1%]; P < .0001) and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < .0001). Efficacy improved beyond week 16 and was maintained through week 52. Adverse event rates with deucravacitinib were similar to those with placebo and apremilast. Limitations: One-year duration, limited racial diversity. Conclusion: Deucravacitinib was superior to placebo and apremilast across multiple efficacy end points and was well tolerated in moderate to severe plaque psoriasis.
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Neil J Korman,Richard B Warren,Jerry Bagel,April W Armstrong,Melinda Gooderham,Bruce Strober,Diamant Thaçi,Akimichi Morita,Shinichi Imafuku,Peter Foley,Howard Sofen,Min Zheng,Lauren Hippeli,Renata M Kisa,Subhashis Banerjee,Andrew Blauvelt

DOI: https://doi.org/10.1080/09546634.2024.2371045

Abstract:Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis evaluated onset of action and maintenance of response in patients randomized to deucravacitinib and placebo only. Methods: Adults with moderate to severe plaque psoriasis at baseline were randomized 1:2:1 to oral placebo, deucravacitinib, or apremilast. Onset of action was determined through changes from baseline in mean PASI, BSA, BSA × sPGA, and DLQI. Maintenance of response was assessed using PASI 75, PASI 90, PASI 100, sPGA 0/1, and sPGA 0 response rates through Week 52 in patients who were treated continuously with deucravacitinib, crossed over from placebo to deucravacitinib at Week 16, or received deucravacitinib and achieved PASI 75 by Week 24. Results: Deucravacitinib showed significantly higher increases in mean percent change from baseline in PASI versus placebo by Week 1. Significant improvement versus placebo was observed in all other efficacy measures by Week 8. Efficacy with deucravacitinib was maintained through Week 52. Conclusion: Deucravacitinib displayed efficacy as early as 1 week and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.
Systemic aspergillosis and mucormycosis in 23 cats

P. Ossent

DOI: https://doi.org/10.1136/VR.120.14.330

1987-04-04

Abstract:The clinical and pathological features of 23 cats with systemic opportunistic mycosis--aspergillosis and mucormycosis--are described. The diagnoses were made post mortem by histology. The history and characteristics of the pathological lesions of the 29 cases of feline mycosis described in the literature are compared with this series. It appears that the incidence of such mycoses is increasing.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials

Mark Lebwohl,Richard B Warren,Howard Sofen,Shinichi Imafuku,Carle Paul,Jacek C Szepietowski,Lynda Spelman,Thierry Passeron,Eleni Vritzali,Andrew Napoli,Renata M Kisa,Alex Buck,Subhashis Banerjee,Diamant Thaçi,Andrew Blauvelt

DOI: https://doi.org/10.1093/bjd/ljae014

IF: 11.113

2024-01-16

British Journal of Dermatology

Abstract:Abstract Background In the phase 3 POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, was well-tolerated and efficacious over 1 year in patients with psoriasis. Objective Evaluate deucravacitinib safety and efficacy over 2 years in patients participating in the phase 3 trials. Methods In the POETYK long-term extension (LTE), an ongoing, phase 3b, open-label trial, adults with moderate to severe plaque psoriasis who completed PSO-1 or PSO-2 receive deucravacitinib 6 mg once daily. Safety was assessed via adverse events (AEs) and laboratory parameter abnormalities. Efficacy endpoints, including ≥75% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment (sPGA) score of 0/1 (clear/almost clear), were evaluated in patients originally randomized to deucravacitinib, patients crossing over from placebo at Week 16, and patients achieving PASI 75 at Week 24 (peak efficacy). Results At data cutoff (October 1, 2021), 1519 patients had received ≥1 dose of deucravacitinib; 79.0% and 39.9% had ≥52 weeks and ≥104 weeks, respectively, of total deucravacitinib exposure. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were similar at 1 year and 2 years, respectively, for any AEs (229.2 vs 154.4), serious AEs (5.7 vs 6.1), discontinuations (4.4 vs 2.8), deaths (0.2 vs 0.4), serious infections (1.7 vs 2.6), herpes zoster (0.9 vs 0.8), major adverse cardiovascular events (0.3 vs 0.4), venous thromboembolic events (0.2 vs 0.1), and malignancies (1.0 vs 0.9). EAIRs for COVID-19 infections were higher at 2 years than at 1 year (5.1 vs 0.5) due to the peak of the global COVID-19 pandemic occurring during the LTE. No clinically meaningful changes from baseline or trends were observed over 2 years in haematologic, chemistry, or lipid parameters. Clinical responses were maintained in patients receiving continuous deucravacitinib treatment from baseline (PASI 75: Week 52, 72.4%; Week 112, 79.7%; sPGA 0/1: Week 52, 57.9%; Week 112, 61.1% [as observed]). Responses at Week 52 were also maintained in placebo crossovers and in Week 24 PASI 75 responders. Conclusions Deucravacitinib maintained efficacy and demonstrated consistent safety with no new safety signals observed through 2 years. (ClinicalTrials.gov identifier: NCT04036435).

dermatology
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial

Shinichi Imafuku,Yukari Okubo,Yayoi Tada,Mamitaro Ohtsuki,Elizabeth Colston,Andrew Napoli,Yanqiu Shao,Subhashis Banerjee,Akimichi Morita

DOI: https://doi.org/10.1111/1346-8138.17074

IF: 3.468

2024-01-26

The Journal of Dermatology

Abstract:Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in Japan for adult patients with plaque (PP), generalized pustular (GPP), and erythrodermic (EP) psoriasis who have had an inadequate response to conventional systemic therapies. This approval is based on results from the global phase 3 POETYK PSO‐1 and PSO‐2 trials in which deucravacitinib was associated with significantly improved efficacy outcomes compared with placebo in adults with moderate to severe plaque psoriasis, and results described here from POETYK PSO‐4, an open‐label, single‐arm, phase 3 trial (NCT03924427), which evaluated the efficacy and safety of deucravacitinib 6 mg once daily in adult Japanese patients with PP, GPP, or EP. The coprimary endpoints were the proportion of patients achieving a ≥75% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75) and a static Physician's Global Assessment score of 0 (clear) or 1 (almost clear) (sPGA 0/1) with at least a two‐point improvement from baseline at week 16. Nonresponder imputation was used for missing data. Efficacy responses, adverse events (AEs), and serious AEs (SAEs) were recorded for up to 52 weeks. Seventy‐four patients were treated (PP, n = 63; GPP, n = 3; EP, n = 8). At week 16, 76.2%, 66.7%, and 37.5% of patients with PP, GPP, and EP, respectively, had achieved PASI 75, and 82.5%, 0.0%, and 50.0% had achieved sPGA 0/1. Responses were overall maintained through week 52. AEs occurred in 74.6% of patients with PP, 100% of patients with GPP, and 87.5% of patients with EP. The most common AEs were nasopharyngitis and acne. Rates of SAEs and discontinuations were low. There were no deaths. Deucravacitinib was effective and well tolerated in Japanese patients with moderate to severe PP and in a limited number of patients with GPP or EP.

dermatology
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation

Luca Potestio,Nello Tommasino,Giuseppe Lauletta,Federica Feo,Angelo Ruggiero,Fabrizio Martora,Antonio Portarapillo,Luigi Guerriero,Matteo Megna

DOI: https://doi.org/10.1080/14740338.2024.2351462

2024-05-07

Expert Opinion on Drug Safety

Abstract:Introduction Nowadays, despite the wide availability of biological drugs and apremilast for psoriasis management, there is always a need for new therapies to customize the therapeutic approach on the basis of the patient's clinical features and comorbidities, especially in order to achieve a prolonged therapeutic response. Thus, new treatment strategies are required to offer patients a personalized approach. In this scenario, major knowledge on psoriasis pathogenesis led to the development of deucravacitinib, an orally administered selective TYK2 inhibitor.

pharmacology & pharmacy
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis

Robert Roskoski Jr

DOI: https://doi.org/10.1016/j.phrs.2022.106642

Abstract:Psoriasis is a heterogeneous, inflammatory, autoimmune skin disease that affects up to 2% of the world's population. There are many treatment modalities including topical medicines, ultraviolet light therapy, monoclonal antibodies, and several oral medications. Cytokines play a central role in the pathogenesis of this disorder including TNF-α, (tumor necrosis factor-α) IL-17A (interleukin-17A), IL-17F, IL-22, and IL-23. Cytokine signaling involves transduction mediated by the JAK-STAT pathway. There are four JAKS (JAK1/2/3 and TYK2) and six STATS (signal transducer and activators of transcription). Janus kinases contain an inactive JH2 domain that is aminoterminal to the active JH1 domain. Under basal conditions, the JH2 domain inhibits the activity of the JH1 domain. Deucravacitinib is an orally effective N-trideuteromethyl-pyridazine derivative that targets and stabilizes the TYK2 JH2 domain and thereby blocks TYK2 JH1 activity. Seven other JAK inhibitors, which target the JAK family JH1 domain, are prescribed for the treatment of neoplastic and other inflammatory diseases. The use of deuterium in the trimethylamide decreases the rate of demethylation and slows the production of a metabolite that is active against a variety of targets in addition to TYK2. A second unique aspect in the development of deucravacitinib is the targeting of a pseudokinase domain. Deucravacitinib is rather specific for TYK2 and its toxic effects are much less than those of the other FDA-approved JAK inhibitors. The successful development of deucravacitinib may stimulate the development of additional pseudokinase ligands for the JAK family and for other kinase families as well.

Exploring Forensic Data with Self-Organizing Maps

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses

Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis

Deucravacitinib for the Treatment of Psoriatic Disease

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients from China Mainland, Taiwan, and South Korea with Moderate to Severe Plaque Psoriasis: a Phase 3 Randomized Clinical Trial

Deucravacitinib in the treatment of psoriasis

Confronting competing demands to improve quality: a five-country hospital survey.

Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis

Improvements in patient‐reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Systemic aspergillosis and mucormycosis in 23 cats

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial

Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation

Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis